Page 137 - Merck Sharp News Today

The LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight | MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, and Others iCrowd Newswire DelveInsights LAG-3-Next Generation Immunotherapy market size, trends, emerging therapies, technological innovations, market barriers, market drivers, ongoing LAG-3-Next Generation Immunotherapy clinical trials, key pharmaceutical companies, collaboration in the space, and actively ...

JW Pharmaceutical Co. has become the first South Korean drug maker to develop the generic version of the latest-generation antibiotic substance, medications m

Lépidémie de coronavirus touche de nombreux pays à travers le monde et le bilan évolue chaque jour. Suivez la situation et les annonces en direct.

/PRNewswire/ -- Hyperledger, an open source collaborative effort created to advance cross-industry blockchain technologies, today announced news from across...

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from its ARTISTRY clinical development program for nemvaleukin alfa (nemvaleukin),...

Global Animal Growth Promoters and Performance Enhancers Market research report encompasses the best market study of market growth and its fluctuating

Snowman Logistics partners with Dr. Reddys for Sputnik vax in India ​ By IANS | ​ 0 Views   Snowman Logistics partners with Dr. Reddys for Sputnik vax in India. Image Source: IANS News New Delhi, June 3 : Snowman Logistics, Indias leading integrated temperature-controlled logistics service provider, in a strategic partnership with the Hyderabad-based Dr. Reddys, will provide temperature-controlled end-to-end logistics solutions for the delivery of the two-dose Sputnik Covid-19 vaccine ac...

Washington, D.C., June 03, 2021 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) today announced that it has awarded its annual Albert B. Sabin...

 E-Mail IMAGE: Toni K. Choueiri, MD, Dana-Farber Cancer Institute, led KEYNOTE-564 clinical trial. Interim results show adjuvant immunotherapy in kidney cancer revealed a 32% decrease in the risk of recurrence or death.... view more  Credit: Dana-Farber Cancer Institute An immunotherapy drug given after surgery improved disease-free survival rates in patients with kidney cancer at high risk of relapse. Interim results of a phase 3 trial of adjuvant therapy revealed a 32% decrease ...

 E-Mail IMAGE: Kenneth Grossmann, MD, PhD, of Huntsman Cancer Institute, led the SWOG S1404 clinical trial, which found that patients with high-risk melanoma who had pembrolizumab after their surgery had a longer... view more  Credit: Huntsman Cancer Institute PORTLAND, OR - Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery....